SG11201408243VA - Compositions and methods for enhancing the efficacy of contraceptive microbicides - Google Patents

Compositions and methods for enhancing the efficacy of contraceptive microbicides

Info

Publication number
SG11201408243VA
SG11201408243VA SG11201408243VA SG11201408243VA SG11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA
Authority
SG
Singapore
Prior art keywords
international
compositions
efficacy
methods
contraceptive
Prior art date
Application number
SG11201408243VA
Inventor
Wendell Guthrie
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408243V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of SG11201408243VA publication Critical patent/SG11201408243VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/187984 A1 (51) International Patent Classification: A61K 9/10 (2006.01) A61K 38/00 (2006.01) A61K 9/14 (2006.01) A61P 31/18 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/032510 15 March 2013 (15.03.2013) English (30) Priority Data: 61/659,368 13 June 2012 (13.06.2012) English US (71) Applicant: EVOFEM, INC. [US/US]; Evofem, Inc., 8910 University Center Lane, Suite 120, San Diego, California 92122 (US). (72) Inventor: GUTHRIE, Wendell; 8910 University Center Lane, Suite 120, San Diego, California 92122 (US). (74) Agents: AXFORD, Laurie A. et al.; Gordon & Rees LLP, 101 West Broadway, Suite 1600, San Diego, California 92101 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) •t 00 o\ l> 00 i-H en i-H o CJ (54) Title: COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES (57) Abstract: The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of mi - crobicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmit - ted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compos­ itions comprising combination a of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
SG11201408243VA 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides SG11201408243VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659368P 2012-06-13 2012-06-13
PCT/US2013/032510 WO2013187984A1 (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Publications (1)

Publication Number Publication Date
SG11201408243VA true SG11201408243VA (en) 2015-01-29

Family

ID=49758600

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408243VA SG11201408243VA (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Country Status (17)

Country Link
US (6) US20150202216A1 (en)
EP (2) EP3308771A1 (en)
JP (2) JP6352907B2 (en)
KR (1) KR102062599B1 (en)
CN (2) CN104487054A (en)
AP (1) AP2014008149A0 (en)
AU (2) AU2013274815B2 (en)
BR (1) BR112014030984B1 (en)
EA (1) EA201590008A1 (en)
HK (1) HK1208809A1 (en)
IL (1) IL235812B (en)
MX (2) MX365905B (en)
NZ (1) NZ703203A (en)
SG (1) SG11201408243VA (en)
UA (1) UA115876C2 (en)
WO (1) WO2013187984A1 (en)
ZA (1) ZA201500111B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202216A1 (en) * 2012-06-13 2015-07-23 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
WO2015095793A1 (en) * 2013-12-19 2015-06-25 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
CN110225750A (en) * 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 The treatment and prevention method of bacterial vaginosis BV
USD920853S1 (en) * 2018-09-14 2021-06-01 Porsche Lizenz—und Handelsgesellschaft mbH & Co. KG Bicycle
US11850303B2 (en) 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (en) * 1986-08-07 1989-12-20 Crinos Industria Farmaco COMPOSITION FOR LOCAL USE WITH ACTS VIRULICIDE, DISINFECTANT AND / OR BACTERICIDE SPERMICIDE
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (en) 1992-12-04 2001-08-27 株式会社紀文フードケミファ Method for separating oligomannuronic acid by degree of polymerization
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (en) 1994-12-22 1997-04-30 Innothera Lab Sa UNITAL GALENIC FORM, PROCESS FOR OBTAINING SAME AND USES THEREOF
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
BRPI0109078B8 (en) * 2000-03-07 2021-05-25 Rush Presbyterian St Lukes Medical Center antimicrobial and contraceptive composition that reduces the risk of transmission or infection by a sexually transmitted disease through sexual activity
JP2009102407A (en) 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd G-rich alginic acid-containing composition
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (en) 2001-05-04 2002-11-04 Univ Pavia COMPOSITIONS WITH CONTROLLED RELEASE OF LACTIC ACID AT VAGINAL LEVEL
US20040242459A1 (en) 2001-06-11 2004-12-02 Forrest Michael J Method for treating inflammatory diseases by administering a ppar-delta agonist
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
JP4712380B2 (en) 2002-07-26 2011-06-29 三笠製薬株式会社 Topical preparation
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2004110461A1 (en) 2003-06-13 2004-12-23 Idh Holding Aps Treatment of symptoms associated with bacterial vaginosis
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (en) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Vaginal suppository eliciting with contraceptive effect
UA93354C2 (en) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
US20100069323A1 (en) 2006-11-10 2010-03-18 Rohto Pharmaceutical Co., Ltd. Composition for application to skin or mucosa
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
CN101677980B (en) 2007-03-30 2013-10-23 莱克瑞股份公司 Use of oligomers of lactic acid in treatment of gynaecological disorders
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
WO2009003189A1 (en) 2007-06-27 2008-12-31 Acresso Software, Inc. A method and system for software virtualization directly from an installation package
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110104262A1 (en) * 2008-04-16 2011-05-05 Cipla Limited Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent
CN101559036B (en) * 2008-04-18 2012-02-08 上海医药工业研究院 Conception control gel composition for vagina as well as preparation method and application thereof
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
BRPI0803568B8 (en) * 2008-08-14 2021-05-25 Biolab San Us Farm Ltda mucoadhesive composition
US20120070476A1 (en) 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
KR20140014264A (en) 2011-05-02 2014-02-05 앱탈리스 파마테크, 인코포레이티드 Rapid dissolve tablet compositions for vaginal adminstration
MX2014000066A (en) 2011-06-28 2014-05-01 Medicis Pharmaceutical Corp High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis.
EP2827854A1 (en) 2012-03-19 2015-01-28 Dr. August Wolff GmbH & Co. KG Arzneimittel Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
US20150202216A1 (en) * 2012-06-13 2015-07-23 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
RU2015110470A (en) 2012-09-14 2016-11-10 Сипла Лимитед PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION, INCLUDING TENOFOVIR, ANTIBACTERIAL AGENT AND OPTIONAL CYCLOPYROX
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
WO2015070072A1 (en) 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
WO2015095793A1 (en) 2013-12-19 2015-06-25 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
US9801839B2 (en) 2014-02-28 2017-10-31 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic method
WO2018049326A1 (en) 2016-09-12 2018-03-15 Evofem Biosciences, Inc. Combination gel for sexually transmitted infections
CN110225750A (en) 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 The treatment and prevention method of bacterial vaginosis BV

Also Published As

Publication number Publication date
BR112014030984A2 (en) 2017-06-27
EA201590008A1 (en) 2015-05-29
EP2861215A4 (en) 2015-04-22
ZA201500111B (en) 2016-01-27
US20200147015A1 (en) 2020-05-14
WO2013187984A1 (en) 2013-12-19
US11439610B2 (en) 2022-09-13
EP3308771A1 (en) 2018-04-18
EP2861215A1 (en) 2015-04-22
AP2014008149A0 (en) 2014-12-31
US20160008276A1 (en) 2016-01-14
CN110693812A (en) 2020-01-17
IL235812B (en) 2020-05-31
UA115876C2 (en) 2018-01-10
AU2013274815A1 (en) 2015-01-22
CN104487054A (en) 2015-04-01
US20190133978A1 (en) 2019-05-09
US20150202216A1 (en) 2015-07-23
JP2018109034A (en) 2018-07-12
US20170128396A1 (en) 2017-05-11
MX2014015307A (en) 2015-07-06
KR102062599B1 (en) 2020-01-06
KR20150018636A (en) 2015-02-23
AU2017206199A1 (en) 2017-08-03
JP2015519395A (en) 2015-07-09
AU2013274815B2 (en) 2017-04-20
US10568855B2 (en) 2020-02-25
US9566232B2 (en) 2017-02-14
JP6352907B2 (en) 2018-07-04
BR112014030984B1 (en) 2022-05-24
HK1208809A1 (en) 2016-03-18
JP6738573B2 (en) 2020-08-12
NZ703203A (en) 2016-07-29
IL235812A0 (en) 2015-01-29
US20230241013A1 (en) 2023-08-03
MX2019007176A (en) 2019-08-16
AU2017206199B2 (en) 2019-03-28
MX365905B (en) 2019-06-18

Similar Documents

Publication Publication Date Title
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408174UA (en) Antibody formulation
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407200TA (en) Liquid formulation
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201408688UA (en) Device with roll mechanism
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201408243VA (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201408509PA (en) Racecadotril lipid compositions
SG11201805755SA (en) Methods of administering hepcidin
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201906557UA (en) Novel stable formulation for fxia antibodies
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction